登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600196 证券简称：复星医药公告编号：临2025-170 上海复星医药（集团）股份有限公司 第十届董事会第十四次会议（临时会议） 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第十届董事会第十四次会议（临时会议）于 2025年11月4日召开，全体董事以通讯方式出席了会议。本次会议的召开符合《中华人民共和国公司 法》、其他有关法律法规和《上海复星医药（集团）股份有限公司章程》的规定。会议审议并达成如下 决议： 一、审议通过关于2025年A股股票期权激励计划首次授予相关事项的议案。 1、根据本公司2025年第一次临时股东会（以下简称"股东会"）已审议通过之《上海复星医药（集团） 股份有限公司2025年A股股票期权激励计划》（以下简称"2025年A股期权计划"）及相关授权，鉴于该 计划下首次授予拟激励对象中的6名已不在本集团（即本公司及控股子公司/单位，下同）任职、不再属 于该计划的激励对象范围，董事会同 ...

2025年11月4日，董事会授出1058.95万份H股受限制股份单位。 复星医药（600196）(02196)公布，鉴于2025年H股受限制股份单位计划所确定的首次授予建议承授人中 的6名已不在集团任职，不再属于合资格雇员范围，根据股东会授权，董事会批准对首次授予的承授人 名单及所涉H股受限制股份单位数量进行调整：即首次授予的承授人由201名调整为195名、首次授予所 涉H股受限制股份单位数量由1069.64万份调整为1058.95万份。 ...

智通财经APP讯，复星医药(02196)公布，鉴于2025 年 H 股受限制股份单位计划所确定的首次授予建议 承授人中的6名已不在集团任职，不再属于合资格雇员范围，根据股东会授权，董事会批准对首次授予 的承授人名单及所涉H股受限制股份单位数量进行调整：即首次授予的承授人由201名调整为195名、首 次授予所涉H股受限制股份单位数量由1069.64万份调整为1058.95万份。 2025 年 11 月 4 日 ，董事会授出1058.95万份H股受限制股份单位。 ...

Core Viewpoint - Fosun Pharma (600196)(02196) plans to adopt a restricted share unit scheme for H-shares in 2025, aiming to incentivize employees through equity participation [1] Summary by Relevant Sections Share Grant Details - The company intends to grant a total of 10.6964 million restricted share units to 201 eligible employees upon the adoption of the plan, with the specific grant date to be determined by the board [1] - The eligible employees can purchase the corresponding number of H-shares at a price of RMB 1.00 per unit after the restricted share units vest [1] Limitations and Allocations - Due to the cap set by the Hong Kong Stock Exchange on H-share plans, the maximum number of restricted share units that can be granted under this plan is 13.3705 million, which corresponds to 13.3705 million H-shares [1] - This represents approximately 0.5007% of the company's total shares and about 2.4716% of the total H-shares (excluding treasury shares) [1]

Summary of the News Article Core Viewpoint The article discusses Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s plan to adopt a restricted share unit scheme for H shares in 2025, aimed at enhancing corporate governance and retaining talent through equity incentives. Group 1: Overview of the Plan - The company plans to implement a 2025 H share restricted share unit scheme to improve corporate governance and establish a long-term incentive mechanism [3][8]. - The total number of restricted share units to be granted under this plan is 13,370,500, which represents approximately 0.5007% of the company's total shares [2][8]. - The initial grant will consist of 10,696,400 restricted share units, accounting for 80% of the total plan [2][8]. Group 2: Details of the Initial Grant - The initial grant will be awarded to 201 eligible employees at a price of RMB 1.00 per unit after the units vest [2][6]. - The total number of shares available for the initial grant represents about 0.4005% of the company's total shares [2][8]. - The plan requires approval from the company's shareholders and the shareholders of its indirect controlling shareholder, Fosun International Limited, before implementation [3][7]. Group 3: Eligibility and Conditions - Eligible employees include executive directors, employee directors, senior management, and other key personnel deemed necessary for motivation [9]. - The plan's effectiveness is contingent upon shareholder approval and compliance with relevant laws and regulations [8][9]. - The vesting schedule for the initial grant is structured over three years, with 33% vesting after 12 months, another 33% after 24 months, and the final 34% after 36 months [17][18]. Group 4: Performance Assessment - The performance assessment for the group will focus on two key indicators: net profit attributable to shareholders and revenue from innovative drugs [20][21]. - The targets for these indicators are set for the upcoming years, with specific financial goals outlined for each assessment period [21][22]. - If the performance metrics are not met, the corresponding restricted share units may not vest [24].